Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Integrating Buprenorphine Into HIV Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by Organization to Achieve Solutions in Substance Abuse (OASIS).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Organization to Achieve Solutions in Substance Abuse (OASIS)
ClinicalTrials.gov Identifier:
NCT00241930
First received: October 17, 2005
Last updated: October 24, 2005
Last verified: August 2005

October 17, 2005
October 24, 2005
September 2005
Not Provided
  • 1.Impact of integrated care vs nonintegrated care on:
  • a. Substance use and high-risk transmission behaviors
  • b. Medical engagement and outcomes
  • c. Psychosocial indices, such as criminal justice, employment, housing, and education
Same as current
Complete list of historical versions of study NCT00241930 on ClinicalTrials.gov Archive Site
  • 1. Acceptability of HIV treatment-based buprenorphine therapy
  • 2. Health services utilization
Same as current
Not Provided
Not Provided
 
Integrating Buprenorphine Into HIV Treatment
SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model

We hypothesize that integrating drug treatment into HIV treatment will improve HIV outcomes as well as drug treatment outcomes in heroin users. This study will test this hypothesis by randomizing patients to two groups. The first group will receive HIV treatment and buprenorphine treatment contemporaneously at their HIV clinic. The second group will receive HIV treatment at their HIV clinic, and go to another facility to receive buprenorphine treatment services.

We will look at HIV outcomes such as CD4 counts, HIV viral loads, and attendance at appointments and drug treatment outcomes such as receipt of buprenorphine and urine toxicology testing.

This study will test the hypothesis that integrating buprenorphine within the context of primary care HIV treatment will improve outcomes for HIV-infected heroin users vs providing buprenorphine services at a separate, off-site facility. As a means of engagement, we will offer the OASIS education group each week at each facility. For those randomized to integrated care, subjects will attend one education session weekly at the time of their HIV clinic. During these sessions, subjects will receive contemporaneous HIV clinic appointments (monthly), case management (monthly), drug counseling (twice monthly), and buprenorphine (which will be dispensed weekly.) For those randomized to separate care, subjects will attend HIV clinic appointments monthly, and will attend weekly education sessions at the OASIS facility. During these sessions, subjects will receive weekly buprenorphine, twice monthly drug counseling, and monthly case management.

We will measure outcomes by reporting attendance, CD4 counts, HIV viral loads, urine toxicology testing on at least a quarterly basis. We will also measure patient satisfaction, knowledge, quality of life, and a number of other outcomes.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Opiate Dependence
  • HIV Infections
Behavioral: Integrating drug treatment into HIV services
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
February 2009
Not Provided

Inclusion Criteria:

  • HIV+ as verified by lab report
  • DSM-IV diagnosis of opioid dependence
  • Speaks/understands English
  • Age 18 years or older

Exclusion Criteria:

  • LFT's (transaminase) >5x ULN
  • DSV-IV criteria for benzodiazepine abuse or dependence within the last month
  • DSM-IV criteria for alcohol dependence within the past 6 months
  • Actively suicidal
  • Methadone dose exceeds level allowing safe transition to buprenorphine
  • Pregnant women and women trying to become pregnant
  • Unable to provide informed consent
  • Clinical judgement that patient is inappropriate
Both
18 Years to 85 Years
No
Contact: Diana L Sylvestre, MD 510-834-5442 dsylves@itsa.ucsf.edu
Contact: Laphyne Barrett 510-834-5442 oasisclinic@sbcglobal.net
United States
 
NCT00241930
H97HA03792, 1 H97HA03792-01-00
Not Provided
Not Provided
Organization to Achieve Solutions in Substance Abuse (OASIS)
Not Provided
Principal Investigator: Diana L Sylvestre, MD Organization to Achieve Solutions in Substance Abuse (OASIS)
Study Director: Ruth Finkelstein, ScD New York Academy of Medicine
Organization to Achieve Solutions in Substance Abuse (OASIS)
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP